Bristol Myers Squibb (BMS) and Hengrui Pharma announced on Tuesday a landmark licensing agreement covering more than a dozen early-stage drug programs. The deal underscores the growing trend of global pharmaceutical companies seeking innovative medicines from China.
The agreement includes a $600 million upfront payment from BMS to Hengrui, with the potential to reach $15.2 billion if all milestones for the included drugs are achieved.
Key Terms of the Partnership
- Drug Rights: BMS will secure the rights to four Hengrui oncology and hematology drug candidates outside mainland China, Hong Kong, and Macau.
- Regional Commercialization: Hengrui will gain the rights to commercialize four immunology drugs from BMS in the same regions.
- Collaborative Development: The companies will jointly advance five additional drugs, with Hengrui leading early clinical development for all programs.
This partnership represents one of the largest collaborations between a global pharma giant and a Chinese biopharmaceutical company to date.
Related articles
STAT+: FDA drug center head Tracy Beth Høeg leaves as agency faces leadership vacuum
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
STAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
STAT+: A political contest in the U.K. could shake up drug pricing
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
STAT+: Top U.S. officials pressured Germany to pay more for prescription drugs
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
STAT+: BeOne wins FDA approval in lymphoma race
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...